• Mon news: Autolus enters CAR-T race with FDA approval. FDA clears clinical hold on Novavax. AbbVie schizophrenia trial failure. Cigna not pursuing Humana. GSK leaving BIO. See more on our front page

Nanobiotix gets FDA fast track status for NBTXR3 to investigate in head and neck cancer

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Feb 11, 2020 at 10:32: AM
via The designation has been granted for the investigation of NBTXR3 activated by radiation therapy, with or without cetuximab, to treat patients with locally advanced head and neck squamous cell cancer (HNSCC) who are not eligible for platinum-based chemotherapy.

article source
 




Top Bottom
Back
Quote